Perseus Proteomics Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2018 - 2020
Revenue	120	100	94	71	67	Upgrade
Revenue Growth (YoY)	20.00%	6.38%	32.39%	5.97%	-21.18%	Upgrade
Cost of Revenue	16	13	7	5	4	Upgrade
Gross Profit	104	87	87	66	63	Upgrade
Selling, General & Admin	336	366	290	231	162	Upgrade
Research & Development	594	616	494	308	313	Upgrade
Operating Expenses	930	982	784	539	475	Upgrade
Operating Income	-826	-895	-697	-473	-412	Upgrade
Interest & Investment Income	1	-	-	-	-	Upgrade
Currency Exchange Gain (Loss)	-2	16	7	9	1	Upgrade
Other Non Operating Income (Expenses)	-3	-1	-	-19	-	Upgrade
EBT Excluding Unusual Items	-830	-880	-690	-483	-411	Upgrade
Asset Writedown	-72	-153	-95	-117	-1	Upgrade
Other Unusual Items	-	-70	-	2	-	Upgrade
Pretax Income	-902	-1,103	-785	-598	-412	Upgrade
Income Tax Expense	2	1	1	1	1	Upgrade
Net Income	-904	-1,104	-786	-599	-413	Upgrade
Net Income to Common	-904	-1,104	-786	-599	-413	Upgrade
Shares Outstanding (Basic)	14	12	12	11	7	Upgrade
Shares Outstanding (Diluted)	14	12	12	11	7	Upgrade
Shares Change (YoY)	21.05%	0.24%	6.94%	57.10%	13.88%	Upgrade
EPS (Basic)	-63.35	-93.65	-66.84	-54.47	-59.00	Upgrade
EPS (Diluted)	-63.35	-93.65	-66.84	-54.47	-59.00	Upgrade
Free Cash Flow	-794	-976	-728	-509	-424	Upgrade
Free Cash Flow Per Share	-55.65	-82.80	-61.91	-46.29	-60.57	Upgrade
Gross Margin	86.67%	87.00%	92.55%	92.96%	94.03%	Upgrade
Operating Margin	-688.33%	-895.00%	-741.49%	-666.20%	-614.93%	Upgrade
Profit Margin	-753.33%	-1104.00%	-836.17%	-843.66%	-616.42%	Upgrade
Free Cash Flow Margin	-661.67%	-976.00%	-774.47%	-716.90%	-632.84%	Upgrade
EBITDA	-824	-892	-692	-471	-	Upgrade
D&A For EBITDA	2	3	5	2	-	Upgrade
EBIT	-826	-895	-697	-473	-412	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.